Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
W Gao, X Wang, Y Zhou, X Wang, Y Yu - Signal transduction and …, 2022 - nature.com
In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of
hematologic malignancies. Approximately half of patients with refractory large B cell …
hematologic malignancies. Approximately half of patients with refractory large B cell …
The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
MD Jain, H Zhao, X Wang, R Atkins… - Blood, The Journal …, 2021 - ashpublications.org
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …
CAR-T cell combination therapy: the next revolution in cancer treatment
In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …
Advancing CAR T cell therapy through the use of multidimensional omics data
Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
A Yilmaz, H Cui, MA Caligiuri, J Yu - Journal of hematology & oncology, 2020 - Springer
Natural killer (NK) cells are a critical component of the innate immune system. Chimeric
antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding …
antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding …